Edition:
United States

People: Melinta Therapeutics, Inc. (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

8.05USD
12:23pm EDT
Change (% chg)

$-1.00 (-11.05%)
Prev Close
$9.05
Open
$8.90
Day's High
$8.95
Day's Low
$8.02
Volume
65,802
Avg. Vol
85,377
52-wk High
$24.25
52-wk Low
$5.20

Baranowski, Lyn 

Ms. Lyn Baranowski is Senior Vice President - Corporate Development and Strategy of the company. She brings to the company her deep life sciences industry experience spanning biotech, pharmaceuticals and venture capital. Prior to joining Melinta, Ms. Baranowski was vice president of commercial development at Pearl Therapeutics and was instrumental in driving the company’s corporate development activities including its recent sale to AstraZeneca. Before her role at Pearl Therapeutics, Ms. Baranowski served as vice president of Vatera Healthcare Partners, a healthcare-focused venture capital firm based in New York, where she was responsible for lead identification, evaluation, and negotiation as well as working with management teams of portfolio companies to develop and implement business plans. Ms. Baranowski previously held public affairs, business development and commercial executive roles at Novartis, including leading the launch of the osteoporosis drug Reclast. Ms. Baranowski holds an MBA from Harvard Business School and a B.A. from American University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --